Articles By Estel Grace Masangkay

31. Malaria Drugs Eyed As Asthma Treatment, Liver Cancer Prevention Tactic 8/4/2014

    Researchers from the National University of Singapore (NUS) recently discovered that two, traditional anti-malaria drugs could be used to treat asthma and prevent liver cancer.

32. Novartis' Vaccinates Over 45K People In Bexsero Campaign 8/1/2014
    Novartis reported high uptake in its first large-scale public Bexsero vaccination program. The campaign was conducted in Quebec’s Saguenay-Lac-Saint-Jean region where the vaccine was offered to everyone aged 2 months through 20 years old.
33. Pfizer To Acquire Baxter's Commercial Vaccines 7/31/2014
    Pfizer announced that it has signed into a definitive agreement to acquire two of Baxter’s marketed vaccines for $636 million. Pfizer will also acquire part of the vaccines’ production facilities in Orth, Austria.
34. PaxVax Acquires Typhoid Vivotif Vaccine, Swiss Plant 7/31/2014
    Specialty vaccine company PaxVax announced that it has acquired the oral typhoid vaccine Vivotif from Crucell Switzerland.
35. DRG Lauds Evolocumab As The Gold-Standard Among PCSK9 Inhibitors 7/28/2014
    A report from the Decision Resources Group gives the gold medal to Amgen’s evolocumab in the race among statin add-on therapies for dyslipidemia in its report Dyslipidemia (in statin-treated patients): Do Physicians Have High Hopes for LDL-lowering Therapies in Cardiovascular Outcomes?
36. Stallergenes Acquires Alergo Pharma, Enlarges Latin American Reach 7/25/2014

    Allergies specialist global healthcare company Stallergenes announced that it has completed an acquisition of the entire share capital of Argentinean allergen immunotherapy (AIT) firm, Alergo Pharma. No financial terms of the agreement were disclosed by either company.

37. Lupin, Other U.S. Firms Consider Bid For GSK Generics 7/25/2014

    Inside sources reveal that Indian pharmaceutical generics firm Lupin, along with other U.S. pharma firms, is considering bidding for GlaxoSmithKline’s auctioned mature and generic drugs.

38. FDA Recalls All Non-Expired Sterile Drugs From Unique Pharma 7/25/2014

    The U.S. Food and Drug Administration (FDA) announced that it is issuing a voluntary, nationwide recall of all non-expired, supposedly sterile drugs produced and distributed by Unique Pharmaceuticals.

39. BMS And Ono Enter Immuno-Oncology Partnership In Asia 7/25/2014

    Bristol-Myers Squibb and Ono Pharmaceuticals announced that the companies have entered an agreement to develop and market Opdivo (nivolumab), Yervoy (ipilimumab), and three other drugs in South East Asia. Ono originally held exclusive rights to nivolumab in the three countries while BMS retained rights in the rest of its territories. The new agreement provides BMS access to Opdivo in the three countries. BMS also held global rights to Yervoy and the three other drugs, namely lirilumab, urelumab, and BMS-986016.

40. MRC Links With 7 Big Pharma Firms For Drug Research 7/24/2014

    The Medical Research Council (MRC) has partnered with seven global big pharma firms to search new uses for deprioritized pharmaceutical compounds. These are AstraZeneca, Eli Lilly & Co., GlaxoSmithKline, Janssen R&D, Pfizer, Takeda, and UCB.